Patient characteristics and type of sequencing for first-line TKI–treated patients diagnosed in CP
| . | All patients . | MMR . | Poor outcome . |
|---|---|---|---|
| N of patients | 46 | 19 | 27 |
| Median age, y (range) | 49 (14-82) | 51 (29-67) | 45 (14-82) |
| Male sex, N (%) | 26 (57) | 9 (47) | 17 (63) |
| Sokal risk group, low/intermediate/high/unknown | 19/11/7/9 | 12/4/2/1 | 7/7/5/8 |
| Additional chromosomal abnormalities at diagnosis, yes/no/unknown | 4/34/8 | 0/18/1 | 4/16/7 |
| First-line TKI, imatinib/nilotinib | 43/3 | 18/1 | 25/2 |
| Best response to TKI therapy, CHR/MCyR/CCyR/MMR/unknown | 8/9/5/20/4 | 0/0/0/19/0 | 8/9/5/1/4 |
| N who developed BC | 26 | 0 | 26 |
| WES plus RNA-Seq, diagnosis/BC | 28/10 | 14/0 | 14/10 |
| WES alone, diagnosis/BC | 2/2 | 0/0 | 2/2 |
| RNA-Seq alone, diagnosis/BC | 16/8 | 5/0 | 11/8 |
| . | All patients . | MMR . | Poor outcome . |
|---|---|---|---|
| N of patients | 46 | 19 | 27 |
| Median age, y (range) | 49 (14-82) | 51 (29-67) | 45 (14-82) |
| Male sex, N (%) | 26 (57) | 9 (47) | 17 (63) |
| Sokal risk group, low/intermediate/high/unknown | 19/11/7/9 | 12/4/2/1 | 7/7/5/8 |
| Additional chromosomal abnormalities at diagnosis, yes/no/unknown | 4/34/8 | 0/18/1 | 4/16/7 |
| First-line TKI, imatinib/nilotinib | 43/3 | 18/1 | 25/2 |
| Best response to TKI therapy, CHR/MCyR/CCyR/MMR/unknown | 8/9/5/20/4 | 0/0/0/19/0 | 8/9/5/1/4 |
| N who developed BC | 26 | 0 | 26 |
| WES plus RNA-Seq, diagnosis/BC | 28/10 | 14/0 | 14/10 |
| WES alone, diagnosis/BC | 2/2 | 0/0 | 2/2 |
| RNA-Seq alone, diagnosis/BC | 16/8 | 5/0 | 11/8 |
CCyR, complete cytogenetic response; CHR, complete hematologic response; MCyR, major cytogenetic response.